Haemonine

Haemonine is a human coagulation factor IX solution for injection, supplied as an intravenous drug in the European market. It contains the active ingredient Human Coagulation Factor IX and is administered by healthcare professionals to replace deficient factor IX and support normal blood clotting.

Haemonine is indicated for the treatment and prevention of bleeding in patients with factor IX deficiency.

- Hemophilia B (congenital factor IX deficiency) - Management of acute bleeding episodes in acquired factor IX deficiency - Peri‑operative prophylaxis for surgical procedures in patients with hemophilia B - Long‑term prophylaxis to reduce the frequency of spontaneous bleeds - Adjunct therapy in patients undergoing major trauma or invasive procedures

Common adverse reactions are generally mild and related to the infusion process.

Common: - Headache - Nausea - Fever or chills - Injection‑site erythema - Transient rise in liver enzymes

Serious: - Development of inhibitors (neutralizing antibodies) to factor IX - Anaphylactic or severe hypersensitivity reactions - Thromboembolic events such as deep‑vein thrombosis - Renal impairment associated with volume overload

Clinicians should consider several safety aspects before initiating Haemonine therapy.

- Assess for a history of inhibitors to factor IX or other clotting factors - Monitor for signs of hypersensitivity during and after infusion - Evaluate renal and hepatic function, especially in patients with comorbidities - Use caution in patients with a predisposition to thrombosis or cardiovascular disease - Adjust dosing in pediatric patients based on weight and clinical response - Ensure proper aseptic technique to prevent infection at the injection site

Haemonine may interact with other agents that affect hemostasis or immune response.

Avoid: - Concurrent use of pro‑coagulant agents (e.g., activated factor VII) that could increase thrombotic risk - Immunosuppressive therapies that may mask hypersensitivity reactions

Use with caution: - Antifibrinolytics such as tranexamic acid, which may augment clot stability - Other plasma‑derived or recombinant clotting factor products - Medications that affect renal clearance, potentially altering plasma levels of factor IX